439 related articles for article (PubMed ID: 28722331)
1. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
Pirro M; Bianconi V; Francisci D; Schiaroli E; Bagaglia F; Sahebkar A; Baldelli F
J Cell Mol Med; 2017 Dec; 21(12):3150-3161. PubMed ID: 28722331
[TBL] [Abstract][Full Text] [Related]
2. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
Hyrina A; Olmstead AD; Steven P; Krajden M; Tam E; Jean F
EBioMedicine; 2017 Sep; 23():68-78. PubMed ID: 28864162
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A.
Li Z; Liu Q
J Gen Virol; 2018 Jan; 99(1):44-61. PubMed ID: 29235977
[TBL] [Abstract][Full Text] [Related]
4. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.
Bridge SH; Sheridan DA; Felmlee DJ; Crossey MM; Fenwick FI; Lanyon CV; Dubuc G; Seidah NG; Davignon J; Thomas HC; Taylor-Robinson SD; Toms GL; Neely RD; Bassendine MF
J Hepatol; 2015 Apr; 62(4):763-70. PubMed ID: 25463543
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
Li Z; Liu Q
Biochem Biophys Res Commun; 2018 Feb; 496(4):1229-1235. PubMed ID: 29397939
[TBL] [Abstract][Full Text] [Related]
6. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
7. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
Syed GH; Tang H; Khan M; Hassanein T; Liu J; Siddiqui A
J Virol; 2014 Mar; 88(5):2519-29. PubMed ID: 24352472
[TBL] [Abstract][Full Text] [Related]
9. Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.
Kuniholm MH; Liang H; Anastos K; Gustafson D; Kassaye S; Nowicki M; Sha BE; Pawlowski EJ; Gange SJ; Aouizerat BE; Pushkarsky T; Bukrinsky MI; Prasad VR
AIDS; 2017 Nov; 31(18):2483-2492. PubMed ID: 29120899
[TBL] [Abstract][Full Text] [Related]
10. Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.
Muzammil K; Hooshiar MH; Varmazyar S; Omar TM; Karim MM; Aadi S; Kalavi S; Yasamineh S
Microb Cell Fact; 2024 Mar; 23(1):90. PubMed ID: 38528584
[TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
[TBL] [Abstract][Full Text] [Related]
12. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia.
Zou Y; Li S; Xu B; Guo H; Zhang S; Cai Y
Inflammation; 2020 Feb; 43(1):251-263. PubMed ID: 31776890
[TBL] [Abstract][Full Text] [Related]
16. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk W; Le May C; Cariou B
Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation.
Gandhi MM; Nguyen KL; Lake JE; Liao D; Khodabakhshian A; Guerrero M; Shufelt CL; Bairey Merz CN; Jordan WC; Daar ES; Bhattacharya D; Chew KW
AIDS; 2024 Mar; 38(3):317-327. PubMed ID: 37788081
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
[TBL] [Abstract][Full Text] [Related]
19. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
Baragetti A; Grejtakova D; Casula M; Olmastroni E; Jotti GS; Norata GD; Catapano AL; Bellosta S
Pharmacol Res; 2018 Apr; 130():1-11. PubMed ID: 29428206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
